| Product Code: ETC8671216 | Publication Date: Sep 2024 | Updated Date: Nov 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Vasudha | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
In 2024, Norway saw significant growth in large molecule drug substance CDMO import shipments, with top exporting countries including the UK, Germany, Denmark, USA, and Metropolitan France. The market concentration, as measured by the Herfindahl-Hirschman Index (HHI), remained low, indicating a diversified import market. The compound annual growth rate (CAGR) from 2020 to 2024 was steady at 3.5%, while the growth rate from 2023 to 2024 surged to an impressive 27.88%. This data suggests a positive outlook for the import market of large molecule drug substances in Norway.

1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Norway Large Molecule Drug Substance CDMO Market Overview |
3.1 Norway Country Macro Economic Indicators |
3.2 Norway Large Molecule Drug Substance CDMO Market Revenues & Volume, 2021 & 2031F |
3.3 Norway Large Molecule Drug Substance CDMO Market - Industry Life Cycle |
3.4 Norway Large Molecule Drug Substance CDMO Market - Porter's Five Forces |
3.5 Norway Large Molecule Drug Substance CDMO Market Revenues & Volume Share, By Service, 2021 & 2031F |
3.6 Norway Large Molecule Drug Substance CDMO Market Revenues & Volume Share, By Source, 2021 & 2031F |
3.7 Norway Large Molecule Drug Substance CDMO Market Revenues & Volume Share, By End-user, 2021 & 2031F |
4 Norway Large Molecule Drug Substance CDMO Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing demand for large molecule drug development services |
4.2.2 Growing trend towards outsourcing drug substance manufacturing |
4.2.3 Technological advancements in biologics and large molecule drug production |
4.3 Market Restraints |
4.3.1 Stringent regulatory requirements for drug substance manufacturing |
4.3.2 High initial capital investment and operational costs |
4.3.3 Limited expertise and capacity in the Norwegian market for large molecule drug substances |
5 Norway Large Molecule Drug Substance CDMO Market Trends |
6 Norway Large Molecule Drug Substance CDMO Market, By Types |
6.1 Norway Large Molecule Drug Substance CDMO Market, By Service |
6.1.1 Overview and Analysis |
6.1.2 Norway Large Molecule Drug Substance CDMO Market Revenues & Volume, By Service, 2021- 2031F |
6.1.3 Norway Large Molecule Drug Substance CDMO Market Revenues & Volume, By Contract Manufacturing, 2021- 2031F |
6.1.4 Norway Large Molecule Drug Substance CDMO Market Revenues & Volume, By Clinical, 2021- 2031F |
6.1.5 Norway Large Molecule Drug Substance CDMO Market Revenues & Volume, By Commercial, 2021- 2031F |
6.1.6 Norway Large Molecule Drug Substance CDMO Market Revenues & Volume, By Contract Development, 2021- 2031F |
6.1.7 Norway Large Molecule Drug Substance CDMO Market Revenues & Volume, By Cell Line Development, 2021- 2031F |
6.1.8 Norway Large Molecule Drug Substance CDMO Market Revenues & Volume, By Process Development, 2021- 2031F |
6.2 Norway Large Molecule Drug Substance CDMO Market, By Source |
6.2.1 Overview and Analysis |
6.2.2 Norway Large Molecule Drug Substance CDMO Market Revenues & Volume, By Mammalian, 2021- 2031F |
6.2.3 Norway Large Molecule Drug Substance CDMO Market Revenues & Volume, By Microbial, 2021- 2031F |
6.2.4 Norway Large Molecule Drug Substance CDMO Market Revenues & Volume, By Others, 2021- 2031F |
6.3 Norway Large Molecule Drug Substance CDMO Market, By End-user |
6.3.1 Overview and Analysis |
6.3.2 Norway Large Molecule Drug Substance CDMO Market Revenues & Volume, By Biotech Companies, 2021- 2031F |
6.3.3 Norway Large Molecule Drug Substance CDMO Market Revenues & Volume, By CRO, 2021- 2031F |
6.3.4 Norway Large Molecule Drug Substance CDMO Market Revenues & Volume, By Others, 2021- 2031F |
7 Norway Large Molecule Drug Substance CDMO Market Import-Export Trade Statistics |
7.1 Norway Large Molecule Drug Substance CDMO Market Export to Major Countries |
7.2 Norway Large Molecule Drug Substance CDMO Market Imports from Major Countries |
8 Norway Large Molecule Drug Substance CDMO Market Key Performance Indicators |
8.1 Number of new partnerships and collaborations in the large molecule drug substance CDMO market |
8.2 Average turnaround time for drug substance manufacturing projects |
8.3 Percentage of revenue reinvested in RD for process improvement and innovation |
9 Norway Large Molecule Drug Substance CDMO Market - Opportunity Assessment |
9.1 Norway Large Molecule Drug Substance CDMO Market Opportunity Assessment, By Service, 2021 & 2031F |
9.2 Norway Large Molecule Drug Substance CDMO Market Opportunity Assessment, By Source, 2021 & 2031F |
9.3 Norway Large Molecule Drug Substance CDMO Market Opportunity Assessment, By End-user, 2021 & 2031F |
10 Norway Large Molecule Drug Substance CDMO Market - Competitive Landscape |
10.1 Norway Large Molecule Drug Substance CDMO Market Revenue Share, By Companies, 2024 |
10.2 Norway Large Molecule Drug Substance CDMO Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |